N
REGN icon

Natixis’s Regeneron Pharmaceuticals REGN Stock Holding History

Natixis’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-396
Closed -$235K – 1161
2022
Q2 		$235K Buy
+396
New +$257K ﹤0.01% 1010

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Natixis's REGN Position: Q2 2026 in Review

Natixis reduced its Regeneron Pharmaceuticals (REGN) stake by 88% in Q2 2026, selling an estimated $33.2M and leaving 6,599 shares worth $4.11M. The position accounts for 0.02% of the portfolio, ranked #483.

Natixis first reported a position in REGN in Q2 2014 and has held it in 34 quarters since. The position peaked at $92.1M in Q1 2022. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Natixis held 6,599 shares of Regeneron Pharmaceuticals worth $4.11M as of Q2 2026.
  • Natixis sold 48,708 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $33.2M.
  • Regeneron Pharmaceuticals made up 0.02% of Natixis's portfolio in Q2 2026, its #483 holding.
  • Natixis first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 34 quarters since.
  • Natixis's Regeneron Pharmaceuticals position peaked at $92.1M in Q1 2022.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.